Olfr685, encoded by the Or52l1 gene, is an olfactory receptor in Mus musculus, classified within the extensive family of G-protein-coupled receptors (GPCRs). These receptors are essential for the sense of smell, detecting odorant molecules in the nasal epithelium and initiating neuronal responses that lead to olfactory perception. Structurally, olfactory receptors like Olfr685 share a 7-transmembrane domain with many neurotransmitter and hormone receptors, making them responsible for the recognition and G protein-mediated transduction of odorant signals. The activation of these receptors by specific odorants leads to various intracellular events, typically involving the modulation of second messengers like cyclic AMP (cAMP). The challenge in inhibiting Olfr685 lies in the complexity of GPCR signaling pathways and the lack of well-characterized direct inhibitors. Therefore, the focus is on potential indirect inhibitors that modulate related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists such as propranolol, atenolol, and metoprolol reduce cellular cAMP levels, crucial in GPCR signaling. This reduction in cAMP may indirectly affect the signaling pathways of GPCRs, potentially influencing the function of olfactory receptors like Olfr685. Calcium channel blockers, including nifedipine and verapamil, alter intracellular calcium levels, another vital factor in GPCR signaling. Changes in calcium dynamics can indirectly influence the function of GPCRs, including olfactory receptors.
Additionally, targeting other GPCR pathways, such as those modulated by angiotensin II receptors, offers another indirect method to influence olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting receptors like Olfr685. Alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine might also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In summary, the indirect inhibition of Olfr685 involves understanding GPCR biology and the interconnected nature of cellular signaling pathways. The listed chemicals provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr685. While direct inhibition remains a significant challenge, these indirect approaches offer potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, lowers cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr685. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, which could indirectly influence GPCR signaling pathways and impact Olfr685 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr685. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr685. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr685. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr685. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr685. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr685. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr685. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr685. | ||||||